Skip to main content

Measuring cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age: a scoping review



Cannabis use among women of reproductive age has increased substantially in recent decades. Understanding reasons for cannabis use in this population is critical for cannabis use prevention efforts. Thus, this scoping review aimed to identify and synthesize current measures on reasons for cannabis use in women of reproductive age.


We searched PubMed, PyschINFO, CINAHL, and Google Scholar for relevant studies published in English between January 2010 and April 2021. Peer-reviewed, quantitative studies reporting on measures of cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age were eligible for inclusion. We excluded studies not focused on women of reproductive age and studies reporting cannabis use prevalence data only.


We included 11 studies (10 primary studies and 1 review) with varying subpopulation samples of women, including non-pregnant women (n = 2), women experiencing infertility (n = 1), pregnant women (n = 4), postpartum women (n = 3), and women in the perinatal period (n = 1). Measurement topic areas included information received from health care professionals, attitudes, perceptions and experiences about cannabis use, knowledge of potential harms, and motivations for cannabis use. Most studies including measures of risk perceptions were conducted among pregnant or postpartum women (n = 4). A single study measured influences of cannabis use; no studies measured social or peer influences of use. Most studies (n = 7) created their own measures, with 2 studies using secondary data via measures from population-based surveillance systems in the United States, and one using a previously validated instrument. Recommendations for future research were centered around addressing knowledge gaps of health effects of cannabis use across different time periods, and etiology of cannabis use.


We found vast measurement gaps in current measures of antecedents of cannabis use among women of reproductive age, providing clear direction for future research in this area. Findings necessitate psychometric evaluation of existing measures to ascertain validity and reliability, as well as development of additional measures of women’s cannabis-related attitudes, perceptions, motivations, and influences. This work is critical to guide not only epidemiologic studies, but cannabis-related prevention work as well.

Peer Review reports


Over the past decade, cannabis use prevalence has increased substantially across the globe [1,2,3]. The United Nation’s World Drug Report, 2020 estimates that in 2018, 192 million people used cannabis in the past year, equating to a global prevalence of roughly 3.9% [4]. North America, Australia and New Zealand, and West and Central Africa have substantially higher cannabis use prevalence, at 14.6%, 10.6%, and 9.3%, respectively [4]. Upticks in cannabis use prevalence are also seen among women of reproductive age, including pregnant and postpartum women [5,6,7]. Large increases in North America, including the United States and Canada have been seen the past decade [2, 8, 9]. In the United States, estimates of past-month cannabis use among non-pregnant women have increased from 11.0% to 2016 to 14.7% in 2019 [10]. Canada has seen a similar trend, with prevalence of cannabis use in women nearly doubling from 6.6 to 11.1% from 2004 to 2017 [11]. Yet, evidence on the etiology of cannabis use, including reasons for and influences of cannabis use among women remains largely unknown [12,13,14].

There is a growing body of evidence exploring women’s cannabis-related knowledge, attitudes, and perceptions of cannabis use [12, 13, 15,16,17,18]. Assessing antecedents of cannabis use among women of reproductive age throughout critical life stages (e.g., adolescence, preconception, prenatal, postpartum) is imperative for the development of tailored and effective cannabis use prevention efforts. However, a robust, in-depth assessment, including psychometric evaluation, of existing measures of these potential reasons for cannabis use in women of reproductive age has not yet been performed. Such a systematic mapping of available measures on antecedents of cannabis use would undoubtedly aid researchers and clinicians in identifying the best measure for their respective purpose and population. This evidence gap, in combination with increasing prevalence of cannabis use among women of reproductive age [2, 8, 9], supports an urgent need to examine the depth and breadth of existing instruments to measure cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age. Further, this gap may also hinder the strength of epidemiologic studies examining women’s cannabis use.

Thus, we aimed to systematically map existing evidence on measures of cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age, including pregnant and postpartum women. This scoping review will also serve as a necessary precursor to determine if a systematic review on this topic should be performed [19].


This scoping review is directly aligned with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist [20].

Protocol and registration

We utilized the scoping review framework by Arksey and O’Malley (2005), as well as recent guidance to increase rigor and reporting of scoping reviews [19,20,21]. The a priori protocol for this review was drafted using the PRISMA extension for Scoping Reviews [20]. Due to the rapid nature of this review, the protocol for this review was not published, but can be accessed by contacting the authors.

Eligibility criteria

To be included in the review, studies needed to examine or report on the development, utilization, or limitations of, measures of cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age. Further, studies were eligible if they focused on women of reproductive age, including, but not limited to women during the preconception (12 months prior to pregnancy), prenatal (during pregnancy), and postpartum (the 12 months after birth) periods. Peer-reviewed studies written in English from any geographical location were included if they were published between 2010 and 2021. Quantitative studies were eligible; mixed-methods studies that included quantitative studies were eligible, but we extracted only quantitative information to be included in the analysis. We also included systematic reviews, with or without meta-analysis, and reviews of the literature if they included quantitative studies. We excluded studies where the population was not women of reproductive age (e.g., biological men, older adults, mixed gender populations) as well as studies that were published before 2010, published as conference abstracts or book chapters, and published in a language other than English. We also excluded studies that did not measure cannabis-related knowledge, attitudes, perceptions, motivations, or influences, as well as studies assessing and reporting on self-reported cannabis use prevalence only. Finally, we excluded reviews that included only qualitative studies.

Information sources

To identify potentially relevant studies, we searched the following databases from January 2010 to March 2021: PubMed, PyschINFO, CINAHL, and Google Scholar. We also included the first 200 results from Google Scholar, when sorted via relevance. We limited our search from 2010 onward due to the changing nature of cannabis, including legalization, so that we captured only contemporary measures in this review. We developed the final search strategy using terms for instruments that have been previously used in systematic reviews (e.g., “questionnaire”, “instrument”, “tool”) [22], incorporating additional terms specific for our population (e.g., “women”, “prenatal”, “pregnant”, “perinatal”, “postpartum”, “breast feeding”) and topic of interest (e.g., “cannabis”, “marijuana”) [23, 24]. We piloted our search strategy for each database to ensure effectiveness in producing relevant articles. After piloting search strategies in each database, we adapted the initial search terms to exclude terms that failed to yield relevant results, which included the following terms: “survey”, “evaluation”, “assessment”, “weed”, and “CBD”. The final search strategy utilized for this scoping review is presented in Additional file 1.

Selection of sources of evidence

We used Covidence Software, an online systematic review management tool, to streamline and manage the review process (Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia). As part of the import process, Covidence automatically de-duplicated citations based on a match of the citation author, title, and date. After search results were imported into Covidence, the review team performed a two-stage review process (title and abstract screening and full-text screening) to screen and identify references eligible for inclusion. Two study team members (KS and ED) piloted the screening process in Covidence on 20 citations, during which we examined both the screening process and reviewer agreement. Then, two members of the research team performed title and abstract screening independently in duplicate. Upon completion of title and abstract screening, we screened potentially relevant studies in their full-text form. We resolved disagreement between reviewers at any stage using consensus and discussion. Studies meeting all inclusion criteria moved forward for data extraction. For each included study, we carried out forward and backward citation searches to identify any potential articles not included via database searching.

Data extraction

The research team developed a detailed data extraction form, which was piloted within Covidence. Two reviewers independently extracted study data and achieved consensus on each item. Using recommendations on relevant data fields for scoping reviews, we extracted the following data: (1) study information (e.g., author, geographic location, dates, purpose, funding); (2) population and context (e.g., study population, setting, method of recruitment); (3) measure/tool/instrument-related data (e.g., tools, measures, psychometric properties); (4) results of pilot or feasibility testing of the measure/tool/instrument; (5) limitations of the study; (6) recommendations for future research; and (7) study conclusions. Given the overall purpose of this scoping review, we did not perform quality assessment on included studies.

Synthesis of results

Based on expected variability in how measure-related information is presented in included studies, we analyzed data both narratively and quantitatively, reporting summary of findings tables that map results in a meaningful manner. For tabular presentation of results, we first stratified by country in which the study was conducted, noting the overall sample, setting, aim, results, and conclusions of each included study. We initially intended to further stratify results by the type of measure used (e.g., knowledge, attitude, perception, motivation, influence). However, as many included studies tapped into multiple domains, this was not feasible. Additionally, we aimed to present, via tabular form and narrative synthesis, findings based on psychometric testing, differentiating between those measures for which validity and reliability have been established versus those measures that did not undergo psychometric testing. Due to the lack of psychometric testing of included measures, this was not possible. We synthesized survey characteristics in both tabular and narrative form, summarizing existing measures based on specific period(s), if any, that the measure was given (e.g., all women of reproductive age, pregnant women, breastfeeding women). We synthesized recommendations for future results and present them in tabular form.


Out of 927 unique citations screened, 11 studies were eligible for inclusion in this review. Figure 1 details the systematic study selection process in accordance with PRISMA guidelines.

Fig. 1
figure 1

PRISMA flow diagram

Key features of included studies

Table 1 describes key features of included studies, including study sample, setting, aim, results, and conclusions. We identified one systematic review [25] and 10 original studies [12,13,14, 26,27,28,29,30,31,32]. Of included studies, 3 were conducted in Canada [13, 26, 27] and 8 were conducted in the United States [14, 25, 28,29,30,31,32]. About 81% of studies (n = 9) were published in the past 4 years [12, 13, 25,26,27,28, 30,31,32]. Studies included samples of women in various life stages; two studies included non-pregnant women only [29, 32] and one included women experiencing infertility only [27]. A majority of studies included women in the perinatal period (n = 8), with some studies specifically focusing on pregnant women (n = 4) [12, 13, 28, 30] or postpartum women (n = 3) [14, 26, 31]. Most studies (n = 8) recruited women from clinics or hospital settings [12,13,14, 26, 28,29,30, 32], with 2 studies performing secondary data analyses reporting data from national surveillance systems in the United States [30, 31].

Table 1 Characteristics of included studies (N = 11)

Measure characteristics

Characteristics of measures, including measurement domain(s), recruitment methods, population, administration modality, and a brief description of the instrument are presented in Table 2. Measurement domains among included studies were perceptions (n = 8) [13, 14, 25, 27,28,29,30,31,32], knowledge (n = 3) [12, 25, 26], attitudes (n = 2) [26, 28], intentions [12], and motivations [12]. More specifically, studies aimed to measure how information received from health care providers influenced cannabis-related decision making [13], attitudes and experiences about using cannabis during childbirth or labor [26], perceptions of cannabis use on infertility [27], risk perceptions of cannabis use [14, 28, 30], negative expectancies associated with cannabis use [29], perceptions of cannabis use and the sexual experience [32], views on cannabis legalization [12, 28], potential influence of legalization on cannabis use [12], knowledge of potential harms [12, 28], and motivations for cannabis cessation [12]. Of studies examining risk perceptions of cannabis use, 4 examined perceptions associated with prenatal cannabis use [12, 14, 28, 30], and one examined risk perceptions among postpartum, breastfeeding women [31].

Table 2 Measure characteristics among included studies (N = 11)

Psychometric evaluation

Most studies created their own survey on women’s cannabis-related knowledge, attitudes, perceptions, and motivations (n = 7) [12,13,14, 27, 28, 30, 32] and did not report evaluating psychometric properties of included measures. However, only one study mentioned piloting the survey for validation purposes [27]. Ng et al. (2020) mention reviewing their survey for readability statistics, but do not mention other methods of psychometric evaluation [28]. Two studies used measures from United States surveillance systems [30, 31] and one study utilized the Marijuana Effect Expectancies Questionnaire (MEEQ), a previously validated instrument [29].

Research and practice recommendations

Included studies had numerous recommendations for both future research and practice (Table 3). Surprisingly, only one study mentioned psychometric evaluation of measures for future research [28]. Common areas of future research to address existing knowledge gaps included future studies with a more robust design (e.g., controlling for co-substance use, homogenous populations) and studies examining the etiology of cannabis use among women, including how women’s attitudes, beliefs, and perceptions play a role in the cannabis-related decision making [12,13,14, 29, 30]. Another recommendation area for future research was examining health care providers’ motives for and influences of cannabis-related recommendations [30, 31].

Most practice recommendations centered on the role of health care providers in preventing potential adverse health outcomes. Specifically, studies recommended that health care providers counsel women about risks of cannabis use to the mother and fetus during pregnancy and postpartum [27, 31, 33, 34]. A single study highlighted that cannabis as a labor analgesic should not be recommended, given absence of safety data [35]. Two studies reiterated the need for public health campaigns that reflected contemporary evidence of risks of prenatal cannabis use [33, 36].

Table 3 Research and practice recommendations of included studies


This is the first review, to our knowledge, to comprehensively examine the breadth of research on measures of antecedents of cannabis use among women of reproductive age. We identified 11 studies reporting on measures of cannabis-related knowledge, attitudes, perceptions, and motivations. We found risk perceptions among pregnant women was the most frequent construct assessed and that most studies were conducted with English-speaking women from hospital or clinic settings. A single study measured the role that health care providers play in women’s cannabis-related decision making. Surprisingly, there were no studies measuring social influences of cannabis use in women. Overall, there was a paucity of evidence, with little to no discussion of psychometric properties of these measures. Thus, we have identified several measurement gaps in this field which future research should aim to address.

In this review, we found a lack of valid, reliable measures to assess antecedents of cannabis use in women of reproductive age, including important maternal health periods, such as the preconception, prenatal, and postpartum periods. With increasing surveillance and research being conducted on women’s cannabis use, the importance of using psychometrically sound measures cannot be understated. Many measures to assess cannabis-related knowledge, perceptions, and motivations in broader, heterogenous populations exist [37,38,39,40]. Undoubtedly, future research could look to validate and test for reliability these existing instruments in subpopulations of women. Future research should also prioritize addressing existing measurement-related gaps of cannabis use among women via the creation of psychometrically sound measures to assess antecedents of cannabis use throughout the life span (e.g., adolescence, young adult, preconception, prenatal, postpartum, parenthood), as these may drastically change over time. Importantly, as most prior research was conducted with English-speaking women in health care settings, future research should look how health disparities and health inequities contribute to prenatal cannabis use. As a start, researchers could aim to examine the psychometric properties of instruments or measures included in this review, which would provide a solid foundation from which future research could build.

The lack of available research on measures of antecedents in women of reproductive age poses a challenge to current and future epidemiologic studies that aim to assess cannabis use. Validated and reliable measures of substance use are critical in the success of longitudinal substance use studies, such as the Adolescent Brain Cognitive Development (ABCD) cohort study [41]. Additionally, the lack of evidence on psychometric properties of existing measures is worrisome, as sound psychometric properties are a necessary prerequisite for utilization of any measure [42]. Several included studies used data from nationally-based surveillance systems in the US. However, many of these measures used have yet to be examined for reliability and validity—yet another important area that future research should examine. There has been much qualitative work conducted in this area [15,16,17, 43]; now researchers should transition to the development and evaluation of quantitative measures. Only after psychometrically sound measures are developed can future work aiming to address associations between antecedents of cannabis use and uptake and continuation of cannabis use begin.

An aim of this scoping review was to elucidate the need for a systematic review on the measures of antecedents of cannabis use among women of reproductive age. Although this is an expanding field, it appears that there is not yet enough empirical evidence to undertake a systematic review. However, researchers could look to conduct a systematic review in this area after this research area has had time to develop and expand. As this is a rapidly growing area of research, we recommend that another scoping review be conducted in 1-2 years and the need for a systematic review be re-evaluated.


There are some limitations of this scoping review. First, we excluded gray literature and studies not published in English, which in turn, could have resulted in failure to identify potentially relevant studies. Second, we utilized date restrictions to capture measures with contemporary relevancy. In doing so, we may have missed in-press or recently published articles yet to be indexed or older articles that may be relevant. Lastly, we attempted to extract psychometric information to include in tabular form in this scoping review but given the lack of psychometric assessment and reporting among included studies, we were unable to do so.


Amid rapidly changing societal norms and policies regarding cannabis use, those aiming to examine and understand women’s attitudes, perceptions, motivations, and influences of cannabis use uptake and use patterns need measures that are valid, reliable, and easy to use. In this scoping review, however, we found a paucity of evidence in this area, with existing measures limited by breadth, depth, and psychometric soundness, posing a measurement challenge. Ideally, psychometrically sound measures of key constructs should be developed prior to the start of cannabis prevention efforts. Thus, the overarching conclusion of this scoping review is that measurement of women’s cannabis-related knowledge, attitudes, perceptions, motivations, and influences should be a focus of this emerging research agenda.

Availability of data and materials

The protocol for this review can be accessed by emailing the corresponding author. All articles included in this review can be accessed online.


  1. Alshaarawy O, Anthony JC. Cannabis use among women of reproductive age in the United States: 2002–2017. Addict Behav. 2019;99:106082.

    Article  Google Scholar 

  2. Corsi DJ, Hsu H, Weiss D, Fell DB, Walker M. Trends and correlates of cannabis use in pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public Health. 2019;110(1):76–84.

    Article  Google Scholar 

  3. Singh S, Filion KB, Abenhaim HA, Eisenberg MJ. Prevalence and outcomes of prenatal recreational cannabis use in high-income countries: a scoping review. BJOG Int J Obstet Gynaecol. 2020;127(1):8–16.

    Article  CAS  Google Scholar 

  4. Nations U. World Drug Report. United Nations publication. 2020.

  5. American College of Obstetricians and Gynecologists Comittee on Obstetric Practice. Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. Obstet Gynecol. 2017;130(4):e205.

  6. Gnofam M, Allshouse A, Metz T. Impact of legalization on prevalence of maternal marijuana use and obstetrical outcomes. American Journal of Obstetrics and Gynecology. 2019;220(1).

  7. Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol. 2015;213(2):201 e1-. e10.

    Article  Google Scholar 

  8. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002-2014. JAMA. 2017;317(2):207–9.

    Article  Google Scholar 

  9. Skelton KR, Hecht AA, Benjamin-Neelon SE. Association of recreational cannabis legalization with maternal cannabis use in the preconception, prenatal, and postpartum periods. JAMA Netw Open. 2021;4(2):e210138.

    Article  Google Scholar 

  10. Administration SAaMHS. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Rockville, MD; 2020. Contract No.: HHS Publication No.PEP20-07-01-001, NSDUH Series H-55.

  11. Lowry DE, Corsi DJ. Trends and correlates of cannabis use in Canada: a repeated cross-sectional analysis of national surveys from 2004 to 2017. CMAJ Open. 2020;8(3):E487.

    Article  Google Scholar 

  12. Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M. Pregnant women’s current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–6.

    Article  Google Scholar 

  13. Bartlett K, Kaarid K, Gervais N, Vu N, Sharma S, Patel T, et al. Pregnant Canadians’ perceptions about the transmission of cannabis in pregnancy and while breastfeeding and the impact of information from health care providers on discontinuation of use. J Obstet Gynaecol Canada. 2020;42(11):1346–50.

    Article  Google Scholar 

  14. Beatty JR, Svikis DS, Ondersma SJ. Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. J Addict Res Ther. 2012;3(4).

  15. Weisbeck SJ, Bright KS, Ginn CS, Smith JM, Hayden KA, Ringham C. Perceptions about cannabis use during pregnancy: a rapid best-framework qualitative synthesis. Can J Public Health. 2020:1–11.

  16. Jarlenski M, Tarr JA, Holland CL, Farrell D, Chang JC. Pregnant women’s access to information about perinatal marijuana use: a qualitative study. Women’s Health Issues. 2016;26(4):452–9.

    Article  Google Scholar 

  17. Latuskie KA, Andrews NC, Motz M, Leibson T, Austin Z, Ito S, et al. Reasons for substance use continuation and discontinuation during pregnancy: a qualitative study. Women Birth. 2019;32(1):e57-e64.

    Article  Google Scholar 

  18. Jarlenski M, Koma JW, Zank J, Bodnar LM, Bogen DL, Chang JC. Trends in perception of risk of regular marijuana use among US pregnant and nonpregnant reproductive-aged women. Am J Obstet Gynecol. 2017;217(6):705–7.

    Article  Google Scholar 

  19. Munn Z, Peters MD, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):1–7.

    Article  Google Scholar 

  20. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Internal Med. 2018;169(7):467–73.

    Article  Google Scholar 

  21. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Social Res Methodol. 2005;8(1):19–32.

    Article  Google Scholar 

  22. Beattie M, Lauder W, Atherton I, Murphy DJ. Instruments to measure patient experience of health care quality in hospitals: a systematic review protocol. Syst Reviews. 2014;3(1):1–8.

    Article  Google Scholar 

  23. Ordean A, Kim G. Cannabis use during lactation: literature review and clinical recommendations. J Obstet Gynaecol Canada. 2020.

  24. Nilvér H, Begley C, Berg M. Measuring women’s childbirth experiences: a systematic review for identification and analysis of validated instruments. BMC Pregnancy Childbirth. 2017;17(1):1–19.

    Article  Google Scholar 

  25. Bayrampour H, Zahradnik M, Lisonkova S, Janssen P. Women’s perspectives about cannabis use during pregnancy and the postpartum period: an integrative review. Prev Med. 2019;119:17–23.

    Article  Google Scholar 

  26. Postonogova T, Xu C, Moore A. Marijuana during labour: a survey of maternal opinions. J Obstet Gynaecol Can. 2020;42(6):774–8.

    Article  Google Scholar 

  27. Jordan T, Ngo B, Jones CA. The use of cannabis and perceptions of its effect on fertility among infertility patients. Hum Reprod Open. 2020;2020(1):hoz041.

    Article  CAS  Google Scholar 

  28. Ng JH, Rice KK, Ananth CV, Brandt JS. Attitudes about marijuana use, potential risks, and legalization: a single-center survey of pregnant women. J Matern Fetal Neonatal Med. 2020:1–9.

  29. Hayaki J, Hagerty CE, Herman DS, de Dios MA, Anderson BJ, Stein MD. Expectancies and marijuana use frequency and severity among young females. Addict Behav. 2010;35(11):995–1000.

    Article  Google Scholar 

  30. Odom GC, Cottler LB, Striley CW, Lopez-Quintero C. Perceived risk of weekly cannabis use, past 30-day cannabis use, and frequency of cannabis use among pregnant women in the United States. Int J Women’s Health. 2020;12:1075.

    Article  Google Scholar 

  31. Coy KC, Haight SC, Anstey E, Grant AM, Ruffo N, Ko JY. Postpartum marijuana use, perceptions of safety, and breastfeeding initiation and duration: an analysis of PRAMS data from seven states, 2017. J Human Lactation. 2021:0890334421993466.

  32. Lynn BK, López JD, Miller C, Thompson J, Campian EC. The relationship between marijuana use prior to sex and sexual function in women. Sex Med. 2019;7(2):192–7.

    Article  Google Scholar 

  33. Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M. Pregnant women’s current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–6.

    Article  Google Scholar 

  34. Bayrampour H, Zahradnik M, Lisonkova S, Janssen P. Women’s perspectives about cannabis use during pregnancy and the postpartum period: an integrative review. Prev Med. 2019;119:17–23.

    Article  Google Scholar 

  35. Postonogova T, Xu C, Moore A. Marijuana during labour: a survey of maternal opinions. J Obstet Gynaecol Canada. 2020;42(6):774–8.

    Article  Google Scholar 

  36. Ng JH, Rice KK, Ananth CV, Brandt JS. Attitudes about marijuana use, potential risks, and legalization: a single-center survey of pregnant women. J Matern-Fetal Neonatal Med. 2020:1–9.

  37. Kolar K, Erickson P, Hathaway A, Osborne G. Differentiating the drug normalization framework: a quantitative assessment of cannabis use patterns, accessibility, and acceptability attitudes among university undergraduates. Subst Use Misuse. 2018;53(14):2339–49.

    Article  Google Scholar 

  38. Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the US: a review. Prev Med. 2017;104:13–23.

    Article  Google Scholar 

  39. Conway FN, Sokolovsky A, White HR, Jackson KM. Simultaneous alcohol and marijuana use: a brief measure of motives. J Stud Alcohol Drugs. 2020;81(2):203–11.

    Article  Google Scholar 

  40. Berg CJ, Payne J, Henriksen L, Cavazos-Rehg P, Getachew B, Schauer GL, et al. Reasons for marijuana and tobacco co-use among young adults: a mixed methods scale development study. Subst Use Misuse. 2018;53(3):357–69.

    Article  Google Scholar 

  41. Lisdahl KM, Sher KJ, Conway KP, Gonzalez R, Ewing SWF, Nixon SJ, et al. Adolescent brain cognitive development (ABCD) study: overview of substance use assessment methods. Dev Cogn Neurosci. 2018;32:80–96.

    Article  Google Scholar 

  42. Kimberlin CL, Winterstein AG. Validity and reliability of measurement instruments used in research. Am J Health-System Pharmacy. 2008;65(23):2276–84.

    Article  Google Scholar 

  43. Holland CL, Rubio D, Rodriguez KL, Kraemer KL, Day N, Arnold RM, et al. Obstetric health care providers’ counseling responses to pregnant patient disclosures of marijuana use. Obstet Gynecol. 2016;127(4):681.

    Article  Google Scholar 

Download references


We would like to acknowledge the authors of each included study, without which this review would not be possible.


This study was funding by Towson University’s Office of Sponsored Programs’ Pilot Research Seed Fund Grant, #15740. The sponsoring agency had no role in the study design, analysis, or manuscript development.

Author information

Authors and Affiliations



KS conceptualized this review, developed the protocol, and was involved in each step of data collection, analysis, and interpretation. KS wrote the initial draft of this manuscript. ED was involved in data collection, including screening and extraction. ED edited and provided feedback on the first draft of the manuscript. SBN provided critical edits to the table design and manuscript. All authors edited and approved the final manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Kara R. Skelton.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

This file presents the full search strategy used in this scoping review.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skelton, K.R., Donahue, E. & Benjamin-Neelon, S.E. Measuring cannabis-related knowledge, attitudes, perceptions, motivations, and influences among women of reproductive age: a scoping review. BMC Women's Health 22, 95 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Marijuana
  • Pregnancy
  • Perinatal
  • Substance use
  • Psychometric properties